Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home ASX Page 18

News & Views

Latest News

Category: ASX

See all

Telix and Heidelberg University Hospital to Develop Next Generation Theranostics

ASX, News,

Telix announces research cooperation agreement with Heidelberg University Hospital to develop next-generation theranostic radiopharmaceuticals for urologic...

Read more

Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product

ASX, News,

Telix has filed a New Drug Submission (NDS) with Health Canada for TLX591-CDx (Kit for the preparation...

Read more

Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data

ASX, News,

Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an Intellectual Property (IP) agreement with the University of Southampton,...

Read more

Telix Granted TGA Priority Review for Prostate Cancer Imaging

ASX, News,

Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of prostate cancer using Positron Emission Tomography...

Read more

Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging

ASX, News,

Telix Pharmaceuticals announces it has entered into a licensing and partnership agreement with...

Read more

Investor Briefing – TheraPharm GmbH Acquisition

ASX, News,

Telix Pharmaceuticals Provides Investor Briefing: TheraPharm GmbH...

Read more

Investor Conference Call: Telix’s acquisition of TheraPharm GmbH

ASX, News,

Telix advises it will hold an investor conference call to provide further detail in relation to Telix’s acquisition of TheraPharm...

Read more

Telix Pharmaceuticals Limited Acquires TheraPharm GmbH

ASX, News,

Telix announces it has entered into an agreement with Scintec Diagnostics GmbH to acquire TheraPharm GmbH, a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of...

Read more

Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA

ASX, News,

Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit for the preparation...

Read more

Investor Briefing: Telix Pharmaceuticals Limited and China Grand Pharma Partnership

ASX, News,

Telix Pharmaceuticals Provides Investor Briefing: Our Asian...

Read more

Posts pagination

1 … 17 18 19 … 23

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings